Bank of New York Mellon Corp Has $70.31 Million Stock Holdings in DaVita Inc. $DVA

Bank of New York Mellon Corp increased its holdings in shares of DaVita Inc. (NYSE:DVA) by 81.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 457,493 shares of the company’s stock after purchasing an additional 204,984 shares during the quarter. Bank of New York Mellon Corp’s holdings in DaVita were worth $70,312,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of DVA. Root Financial Partners LLC lifted its stake in DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares in the last quarter. Caitlin John LLC purchased a new stake in shares of DaVita in the fourth quarter worth approximately $34,000. Sankala Group LLC purchased a new stake in shares of DaVita in the fourth quarter worth approximately $39,000. Canada Pension Plan Investment Board acquired a new stake in shares of DaVita during the second quarter worth approximately $43,000. Finally, Kestra Advisory Services LLC purchased a new position in DaVita during the fourth quarter valued at approximately $45,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.90% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on DVA. Truist Financial upped their price objective on shares of DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Barclays boosted their price target on shares of DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. UBS Group lifted their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Finally, TD Cowen upped their target price on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $216.50.

DaVita Trading Down 2.4%

NYSE:DVA opened at $231.56 on Thursday. The firm has a market capitalization of $14.87 billion, a PE ratio of 21.48, a PEG ratio of 0.78 and a beta of 0.88. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $239.64. The firm’s fifty day simple moving average is $212.06 and its 200 day simple moving average is $167.40.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same period last year, the business posted $2.00 earnings per share. The firm’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts anticipate that DaVita Inc. will post 15.07 EPS for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.